Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 3Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Peritoneal Neoplasms 1Osteosarcoma 1Liver, Cancer of, Primary Resectable 1Hepatocellular Carcinoma Resectable 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1Acute Toxic Effects 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × lobaplatin × Clear all
NCT03613753 2020-02-05

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
72 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡